WO2014089121A3 - Retrograde delivery of cells and nucleic acids for treatment of cardiovascular diseases - Google Patents

Retrograde delivery of cells and nucleic acids for treatment of cardiovascular diseases Download PDF

Info

Publication number
WO2014089121A3
WO2014089121A3 PCT/US2013/072934 US2013072934W WO2014089121A3 WO 2014089121 A3 WO2014089121 A3 WO 2014089121A3 US 2013072934 W US2013072934 W US 2013072934W WO 2014089121 A3 WO2014089121 A3 WO 2014089121A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
nucleic acids
treatment
cardiovascular diseases
retrograde delivery
Prior art date
Application number
PCT/US2013/072934
Other languages
French (fr)
Other versions
WO2014089121A2 (en
Inventor
Thomas Ichim
Amit Patel
Original Assignee
Thomas Ichim
Amit Patel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Ichim, Amit Patel filed Critical Thomas Ichim
Publication of WO2014089121A2 publication Critical patent/WO2014089121A2/en
Publication of WO2014089121A3 publication Critical patent/WO2014089121A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Methods, compositions of matter, medical devices, and kits useful for the treatment of cardiovascular conditions are disclosed comprising of administering cells and/or nucleic acids into the cardiac venous system in a retrograde manner so as to obtain tissue perfusion of said cells and/or nucleic acids. In one embodiment, administration of endometrial regenerative cells in a retrograde manner is disclosed. Additionally, nucleic acids capable of suppressing inflammation and/or inhibition of pathological remodeling may be administered alone or in combination with said cells.
PCT/US2013/072934 2012-12-03 2013-12-03 Retrograde delivery of cells and nucleic acids for treatment of cardiovascular diseases WO2014089121A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261732439P 2012-12-03 2012-12-03
US61/732,439 2012-12-03

Publications (2)

Publication Number Publication Date
WO2014089121A2 WO2014089121A2 (en) 2014-06-12
WO2014089121A3 true WO2014089121A3 (en) 2014-07-31

Family

ID=50884132

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/072934 WO2014089121A2 (en) 2012-12-03 2013-12-03 Retrograde delivery of cells and nucleic acids for treatment of cardiovascular diseases

Country Status (1)

Country Link
WO (1) WO2014089121A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104928235A (en) * 2015-07-10 2015-09-23 奥思达干细胞有限公司 Composition based on stem cells and application thereof in preparing preparation for coronary heart disease
CA3004742A1 (en) * 2015-11-11 2017-05-18 Intrexon Corporation Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies
WO2017201342A1 (en) * 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
CN107663513B (en) * 2016-07-27 2021-05-07 上海坤爱生物科技股份有限公司 Efficient separation and extraction method for uterine membrane stem cells and library building method
WO2018119185A1 (en) * 2016-12-23 2018-06-28 StemBios Technologies, Inc. Use of somatic stem cells for increasing heme oxygenase level
US20190314408A1 (en) * 2016-12-23 2019-10-17 StemBios Technologies, Inc. Use of somatic stem cells for reducing il-6 level
CN107260949A (en) * 2017-06-28 2017-10-20 鹿志霞 A kind of Chinese medicine for treating gestational period hapamnion
CN110423721B (en) * 2018-05-01 2024-02-27 云南济慈再生医学研究院有限公司 Preparation method and application of younger repair type fibroblast
CN112770754A (en) * 2018-07-26 2021-05-07 加利福尼亚大学董事会 Treatment of vascular obstruction by activation of Notch signaling
CN109852689B (en) * 2019-04-03 2022-02-18 上海交通大学医学院附属第九人民医院 Group of vascular malformation related biomarkers and related detection kit
CN112444627B (en) * 2019-09-05 2022-03-29 四川大学华西医院 High-risk chest pain screening kit
EP4234019A3 (en) * 2019-10-18 2023-09-13 Amniotics AB Processes and apparatuses for obtaining amniotic mesenchymal stem cells from amniotic fluid and cells derived thereof
EP4150084A1 (en) 2020-05-11 2023-03-22 Genentech, Inc. Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same
JP2023527684A (en) 2020-05-11 2023-06-30 ジェネンテック， インコーポレイテッド Complement component C1S inhibitors for treating neurological disorders and related compositions, systems and methods of using same
EP4150085A1 (en) 2020-05-11 2023-03-22 Genentech, Inc. Complement component c1r inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
KR20230119130A (en) 2020-12-14 2023-08-16 리제너론 파마슈티칼스 인코포레이티드 Methods of Treating Metabolic Disorders and Cardiovascular Disease with Inhibin Subunit Beta E (INHBE) Inhibitors
AU2021410768A1 (en) 2020-12-23 2023-06-22 Regeneron Pharmaceuticals, Inc. Treatment of liver diseases with cell death inducing dffa like effector b (cideb) inhibitors
CN117919400B (en) * 2024-03-22 2024-05-28 再少年(北京)生物科技有限公司 IPS induced directional differentiation endothelial progenitor cell and antibody combined treatment of cardiovascular and cerebrovascular diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063654A1 (en) * 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
EP1707622A1 (en) * 2004-01-20 2006-10-04 Universidad Autonoma De Madrid Ciudad Universitaria Cantoblanco Use of compounds that regulate hdac6 tubulin deacetylase activity in the preparation of pharmaceutical compositions, method of identifying the aforementioned regulating compounds, said pharmaceutical compounds and applications thereof
WO2009029688A2 (en) * 2007-08-27 2009-03-05 Boston Biomedical, Inc. Compositions of asymmetric interfering rna and uses thereof
US20090123433A1 (en) * 2006-03-07 2009-05-14 Geeta Shroff Compositions Comprising Human Embryonic Stem Cells and their Derivatives, Methods of Use, and Methods of Preparation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063654A1 (en) * 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
EP1707622A1 (en) * 2004-01-20 2006-10-04 Universidad Autonoma De Madrid Ciudad Universitaria Cantoblanco Use of compounds that regulate hdac6 tubulin deacetylase activity in the preparation of pharmaceutical compositions, method of identifying the aforementioned regulating compounds, said pharmaceutical compounds and applications thereof
US20090123433A1 (en) * 2006-03-07 2009-05-14 Geeta Shroff Compositions Comprising Human Embryonic Stem Cells and their Derivatives, Methods of Use, and Methods of Preparation
WO2009029688A2 (en) * 2007-08-27 2009-03-05 Boston Biomedical, Inc. Compositions of asymmetric interfering rna and uses thereof

Also Published As

Publication number Publication date
WO2014089121A2 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
WO2014089121A3 (en) Retrograde delivery of cells and nucleic acids for treatment of cardiovascular diseases
BR112013027119A2 (en) new ligand-drug conjugates (adcs) and their use
EA201792541A3 (en) INHIBITORS OF BILATERIC ACIDS RECIRCULATION FOR THE TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC DISEASE OF THE LIVER
MX2020005345A (en) Methods for treating cancer and non-neoplastic conditions.
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
IN2014KN00996A (en)
WO2012023623A3 (en) Agent for treatment of hunter syndrome
SV2011003901A (en) ARILO COMPOUNDS WITH HETEROCYCLIC SUBSTITUTES AS HIF INHIBITORS
NZ702169A (en) The use of heat shock protein 90 (hsp90) modulators for the treatment of metabolic syndrome
MX2015002239A (en) Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions.
PA8794401A1 (en) 6-PHENYLNICOTINIC ACIDS SUBSTITUTED AND ITS USE
WO2014040052A3 (en) Glycyrrhetinic acid derivatives with anti-inflammatory activity
BR112014003071A2 (en) treatment of peripheral vascular disease using umbilical cord tissue derived cells
WO2015099838A3 (en) Compositions and methods of treating ocular diseases
CO7151496A2 (en) Therapeutic agents for optimized subcutaneous administration
EP4008786A3 (en) The mirna-212/132 family as a therapeutic target
MX2015015036A (en) Methods for improving lipid profiles using atrasentan.
WO2015003122A3 (en) Regulation of glucose metabolism using anti-cgrp antibodies
MA40846A (en) COMPOSITIONS OF FATTY ACIDS AND SELF-MICELLIZING FATTY ACID ESTERS, AS WELL AS THEIR USE IN THE TREATMENT OF DISEASE CONDITIONS
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX2010008433A (en) Use of ranolazine for the treatment of cardiovascular diseases.
NZ588886A (en) Use of dronedarone alone or in combination for preparing a medicament for the treatment of patients with arrhythmia and having an increase of creatinine level
EA201590825A1 (en) WAYS OF CONTROLING BLOOD PRESSURE AND REDUCING DISPERSE IN HEART FAILURE
Cheng et al. Advances in the research of fungal sinusitis
UA56368U (en) Method for treatment of patients with chronic cardiac insufficiency of coronarogenic genesis with concomitant anaemia

Legal Events

Date Code Title Description
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 30/09/2015)

122 Ep: pct application non-entry in european phase

Ref document number: 13859799

Country of ref document: EP

Kind code of ref document: A2